Canadian guideline for Parkinson disease

作者：David A. Grimes, Megan J. Fitzpatrick, Joyce Gordon, Janis M. Miyasaki, Edward A. Fon, Michael G. Schlossmacher, Oksana Suchowersky, Alexander H. Rajput, Anne Louise Lafontaine, Tiago Mestre, Silke Appel‐Cresswell, Suneil Kumar Kalia, Kerrie L. Schoffer, Mateusz Zurowski, Ronald B. Postuma, Sean Jeremy Udow, Susan Helen Fox, Pauline Barbeau, Brian F. Hutton · 发表于：Canadian Medical Association Journal · 年份：2019 · DOI：10.1503/cmaj.181504 · 被引用次数：174 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Botulinum Toxin and Related Neurological Disorders、Medical Research and Practices

[See related article at [www.cmaj.ca/lookup/doi/10.1503/cmaj.191089][2]][2] KEY POINTS Parkinson disease is chronic and progressive in nature, decreasing the quality of life for both patients with the disease and their caregivers and placing an onerous economic burden on society.[1][2] The first